The upgrade to Outperform suggests that TD Cowen sees positive momentum or potential in Surgery Partners' stock, which could lead to increased investor interest and a potential rise in the stock price in the short term. However, the reduction in the price target might temper some of the positive sentiment, as it implies a more conservative valuation than previously estimated.